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a b s t r a c t 
The transcriptomic dataset (whole genome microarray 
Affymetrix Human U133 plus 2.0 and Affymetrix Mouse 
Genome 430 2.0) presented in this paper describes the dif- 
ferential gene expression profile of a human in vitro model 
of drug-induced cholestasis and a well-known mouse in vivo 
model of cholestasis. The in vitro model consists of human 
hepatoma HepaRG cells in monolayer configuration exposed 
to 3 different cholestatic drugs with or without bile acids. For 
in vivo modelling of cholestasis, mice were subjected to bile 
duct ligation surgery. Consecutive normalization, summariza- 
tion and background adjustments have been made by means 
of Robust Multichip Average Express software. 
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Subject Pharmacology, Toxicology and Pharmaceutical Science: Toxicology; Medicine 
and Dentistry: Hepatology 
Specific subject area Cholestatic liver injury 
Type of data Raw data 
How data were acquired Affymetrix GeneChip Human Genome U133 plus 2.0 array (ThermoFisher, 
Belgium) 
Affymetrix GeneChip Mouse Genome 430 2.0 array (ThermoFisher, Belgium) 
Ingenuity Pathway Analysis (IPA) (Qiagen, Belgium) 
Transcriptome Analysis Console (TAC) (ThermoFisher, Belgium) 
Data format Raw (.CEL), normalized and analyzed 
Parameters for data collection Male 8-weeks-old Sv129 mice (Harlan, The Netherlands) were housed in the 
animal facility of the Faculty of Medicine and Health Sciences (Ghent 
University, Belgium). Mice were allowed to acclimatize for at least 1 week 
prior to experiments. Care was given in accordance with the Federation for 
Laboratory Animal Science Associations guidelines and the national guidelines 
for animal protection. The animal protocols used in this study were evaluated 
and approved by the Ethical Committee of Experimental Animals at the Faculty 
of Medicine and Health Sciences, Ghent University, Belgium (ECD 15/36). 
Cholestasis was induced by performing bile duct ligation (BDL) surgery as 
previously described [1] . Control mice were sham operated, whereby the 
common bile duct was isolated, but not ligated. Liver samples were collected 6 
weeks post-surgery. 
Cryopreserved differentiated HepaRG cells (Biopredic International, France) 
were cultured following manufacturer’s instructions (Biopredic International, 
France). Hereafter, HepaRG cells were exposed to 60 μM atazanavir, 20 μM 
cyclosporin A and 30 μM nefazodone. A 50 times concentrated mixture of 5 
bile acids ( i.e. 66 μM glycochenodeoxycholic acid, 20 μM deoxycholic acid, 
19.5 μM chenodeoxycholic acid, 19 μM glycodeoxycholic acid, and 17.5 μM 
glycocholic acid) was included in the cell culture medium of HepaRG cells 
from day 7 after seeding in combination with the drug. Incubations with drugs 
were routinely carried out for 72 h with daily renewal of cell culture media, 
including a 50 times concentrated bile acid mixture and drugs. Dimethyl 
sulfoxide (DMSO) treated HepaRG cells served as control. All conditions 
contained a final DMSO concentration of 0.25%. All compounds were purchased 
from Sigma Aldrich, Belgium. 
Description of data collection Total RNA was extracted from HepaRG cell culture samples that were treated 
with atazanavir, cyclosporin A and nefazodone in the absence or presence of a 
50 times concentrated mixture of bile acids ( i.e. ATA 60 μM, ATA + BA 60 μM, 
CsA 20 μM, CsA + BA 20 μM, NEFA 30 μM and NEFA + BA 30 μM), as well as 
from controls solely exposed to the 50 times concentrated bile acid mixture of 
bile acids and/or identical DMSO concentration ( i.e. BA and CTL, respectively). 
For each condition samples were collected from 3 separate HepaRG batches 
( n = 3). Similarly, total RNA was extracted from liver samples of mice that 
underwent bile duct ligation ( i.e. BDL) and sham surgery ( i.e. CTL). Liver 
samples were collected from 6 BDL mice and 6 CTL mice ( n = 6). Quantification 
and purity of the isolated RNA were determined via spectrophotometric 
analysis with a Nanodrop spectrophotometer (ThermoFisher Scientific, 
Belgium). Whole genome expression analysis was performed using microarray 
technologies (Affymetrix, Germany). 
Data source location Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit 
Brussel, Jette, Belgium. 
Data accessibility Raw data is available at the Gene Expression Omnibus (GEO) from The National 
Center for Biotechnology Information (NCBI) with access number GSE152494. 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152494 
Related research article E. Gijbels, V. Vilas-Boas, P. Annaert, T. Vanhaecke, L. Devisscher, M. Vinken, 
Robustness testing and optimization of an adverse outcome pathway on 
cholestatic liver injury. Arch Toxicol 94 (4): 1151–1172 (2020). 
10.10 07/s0 0204 –020 –02691 –9 [3] 
alue of the data 
• The data provide the transcriptomic signature of drug-induced cholestasis in vitro and ob-
structive cholestasis in vivo . 





































• The data can support further research of the mechanistic basis of different types of cholesta-
sis. 
• Comparison of the transcriptomic signatures of other types of cholestasis will shed new light
onto similar and dissimilar features of cholestasis types, which may serve as foundation for
novel diagnostic strategies. 
• The data assist in the assessment of the robustness of an adverse outcome pathway on
cholestatic liver injury. 
Data description 
Raw data are provided from whole genome transcriptomic analysis performed via microar-
ray on 3 different batches of HepaRG cells exposed to 3 different cholestatic drugs, atazanavir
( i.e. datasets ATA 60 μM 1-3), cyclosporin A ( i.e. datasets CsA 20 μM 1-3) and nefazodone ( i.e.
datasets NEFA 30 μM 1-3) in absence or presence of a 50 times concentrated bile acid mix-
ture ( i.e. datasets ATA 60 μM + BA 1-3; CsA 20 μM + BA 1-3 and NEFA 30 μM + BA 1-3). Controls
consist of HepaRG cells solely exposed to the vehicle ( i.e. datasets CTL 1-3) and the 50 times
concentrated bile acid mixture ( i.e. datasets BA 1-3). 
In parallel, whole genome transcriptomic data was also achieved from bile duct ligated
mice ( i.e. datasets CBDL1-6) and sham mice ( i.e. datasets SHAM1-6). Data was obtained using
Affymetrix Human Genome U133 plus 2.0 and Affymetrix Mouse Genome 430 2.0, which, in
turn, were processed by the software program Robust Multichip Average (RMA) Express. 
Experimental design, materials and methods 
Male 8-weeks-old Sv129 mice were subjected to bile duct ligation surgery. In brief, animals
were anaesthetized with isoflurane inhalation (Isoflo, Abbott, Belgium). Once fully sedated, a
midline abdominal incision was made, after which the common bile duct could be isolated and
ligated between 2 knots of non-resorbable suture (Silkan 5/0, Braun Aesculap, Germany), as pre-
viously described [1] . Control mice were sham operated, whereby the common bile duct was
isolated, but not ligated. Liver samples were collected 6 weeks post-surgery. 
Cryopreserved differentiated HepaRG cells (Biopredic International, France) were thawed and
seeded in basal hepatic medium supplemented with thaw seed and general purpose medium
(Biopredic International, France) onto rat tail collagen (0.1mg/ml) (Corning, Sigma Aldrich,
Belgium) coated 24-well plates following manufacturer’s instructions. Hereafter, HepaRG cells
needed to be refreshed every 2–3 days with basal hepatic medium supplemented with main-
tenance and metabolism medium (Biopredic International, France). At day 7, HepaRG cells were
exposed to cholestatic concentrations of atazanavir (60 μM), cyclosporin A (20 μM), and nefa-
zodone (30 μM) (Sigma Aldrich, Belgium) with or without a 50 times concentrated bile acid
mixture ( i.e. 66 μM glycochenodeoxycholic acid, 20 μM deoxycholic acid, 19.5 μM chenodeoxy-
cholic acid, 19 μM glycodeoxycholic acid, and 17.5 μM glycocholic acid (Sigma Aldrich, Belgium))
added to the cell culture medium. Stock solutions were made of the drugs and bile acids in
DMSO. The final incubation solutions were prepared ex tempore by diluting the stock solutions
with basal hepatic medium supplemented with induction serum-free medium (Biopredic Inter-
national, France) and contained a final DMSO concentration of 0.25%. After 72 h of exposure,
samples were collected for RNA isolation by aspirating the cell culture medium and adding ly-
sis buffer (lysis solution with 1% β-mercaptol) directly to the well (Qiagen, Belgium). Total RNA
extraction (Qiagen, Belgium) was done according to manufacturer’s instructions to both in vitro
and in vivo samples. Quantification and purity of the isolated RNA were determined by means of
spectrophotometric analysis with a NanoDrop® ND-100 Spectrophotometer (ThermoFisher Sci- 
entific, Belgium). A cut-off ratio between 1.8 and 2.1 for the absorption at 260/280 nm was used 
for assessing purity. 































[  Whole genome expression analysis was performed using microarray technologies from
ffymetrix (Germany) as previously described [2] . For this purpose, 100 ng total RNA per sam-
le was amplified using a GeneChip 3 ′ IVT Express Kit following manufacturer’s instructions
Affymetrix, Germany). Amplified RNA was purified with magnetic beads and 15 mg biotin-
mplified RNA was treated with fragmentation reagent. Then, 12.5 μg of fragmented ampli-
ed RNA was hybridized to Affymetrix Human genome U133 plus 2.0 GeneChip and Affymetrix
ouse Genome 430 2.0 GeneChip. Subsequently, the chips were placed in a GeneChip Hybridiza-
ion Oven 645 (Affymetrix, Germany) following manufacturer’s instructions. After incubation, the
rrays were washed with GeneChip Fluidics Station 450 (Affymetrix, Germany) and stained with
ffymetrix HWS kit. Thereafter, stained arrays were scanned via an Affymetrix GeneChip Scanner
0 0 0 7G. Hybridzation controls were performed using Affymetrix GCOS software. Normalization
uality controls, such as scaling factors, background intensities, noise and raw Q-values, aver-
ge intensities and present calls were done with RMA Express software and were all within the
cceptable limits. 
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